Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Unknown 1Terminated 1Recruiting 1

Sponsor Class

OTHER 43INDUSTRY 3NIH 1

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Gynecologic 1CNS 1Breast 1

Conditions

Neoplasms 2875Carcinoma, Non-Small-Cell Lung 2428Breast Neoplasms 2068Colorectal Neoplasms 1247Neoplasm Metastasis 1232Prostatic Neoplasms 1080Melanoma 974Multiple Myeloma 963Ovarian Neoplasms 904Recurrence 852Leukemia, Myeloid, Acute 810Lung Neoplasms 758Pancreatic Neoplasms 753Lymphoma, Non-Hodgkin 727Lymphoma 660Stomach Neoplasms 623Carcinoma, Hepatocellular 566Carcinoma, Renal Cell 546Squamous Cell Carcinoma of Head and Neck 529Leukemia, Lymphocytic, Chronic, B-Cell 493Lymphoma, Follicular 468Head and Neck Neoplasms 451Glioblastoma 436Advanced Solid Tumors 432Small Cell Lung Carcinoma 411Triple Negative Breast Neoplasms 410Lymphoma, Large B-Cell, Diffuse 398Leukemia 394Uterine Cervical Neoplasms 369Advanced Solid Tumor 351

Interventions

Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Neoplasms, Second Primary × Clear all
NCT06562647 2026-02-13

SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors

Cell Origin Biotech (Hangzhou) Co., Ltd.

Phase NA Recruiting
2 enrolled
Gynecologic

Ovarian Neoplasms, Neoplasms, Second Primary

NCT05664009 2024-04-05

The Safety and Efficacy of Redsenol-1 Plus on Cancer-related Fatigue in Adults

Canada Royal Enoch Phytomedicine Co., Ltd.

Phase 2 Unknown
72 enrolled

Fatigue, Neoplasms, Second Primary

NCT00638963 2017-06-14

STOP

Merck Sharp & Dohme LLC

Phase 2 Terminated
6 enrolled 9 charts
BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡